Front Street Capital Management Inc. Has $11.30 Million Position in Enovis Co. (NYSE:ENOV)

Front Street Capital Management Inc. increased its position in Enovis Co. (NYSE:ENOV - Free Report) by 12.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 257,513 shares of the company's stock after purchasing an additional 28,624 shares during the quarter. Enovis accounts for 2.0% of Front Street Capital Management Inc.'s portfolio, making the stock its 17th largest position. Front Street Capital Management Inc. owned 0.45% of Enovis worth $11,300,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Enovis by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock valued at $240,731,000 after acquiring an additional 75,348 shares during the period. DAVENPORT & Co LLC lifted its stake in Enovis by 6.0% in the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock valued at $121,181,000 after buying an additional 157,216 shares during the last quarter. Royce & Associates LP boosted its holdings in shares of Enovis by 2.8% during the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock valued at $108,409,000 after acquiring an additional 66,891 shares during the period. River Road Asset Management LLC increased its holdings in shares of Enovis by 3.8% in the 4th quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock worth $54,339,000 after acquiring an additional 45,762 shares during the period. Finally, Boston Partners boosted its stake in Enovis by 27.1% during the 4th quarter. Boston Partners now owns 1,048,532 shares of the company's stock valued at $46,034,000 after purchasing an additional 223,816 shares during the period. Institutional investors and hedge funds own 98.45% of the company's stock.

Enovis Stock Performance

Shares of ENOV stock traded up $1.62 during mid-day trading on Wednesday, reaching $34.24. The stock had a trading volume of 380,690 shares, compared to its average volume of 742,432. The firm has a market cap of $1.96 billion, a PE ratio of -15.63 and a beta of 1.86. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a one year low of $29.32 and a one year high of $56.43. The firm's 50 day simple moving average is $37.08 and its 200 day simple moving average is $42.06.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.92 by $0.06. The business had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, analysts forecast that Enovis Co. will post 2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a "buy" rating and set a $64.00 target price on shares of Enovis in a research note on Wednesday, April 9th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.